New Delhi | August 2026. For thousands of Indian families, a diagnosis of prostate cancer brings fear, uncertainty and difficult decisions. For many men—particularly those diagnosed while still professionally active and supporting their families—the greatest concern is often not cancer alone, but whether treatment will permanently affect urinary control, sexual function, independence and overall quality of life.

A landmark international clinical study, together with scientific discussions at SOGOCON 2026, is now providing encouraging long-term evidence that, for carefully selected patients, organ-preserving focal High-Intensity Focused Ultrasound (HIFU) can effectively control localized prostate cancer while preserving quality of life.

Published in the prestigious journal European Urology, the study represents one of the world’s largest and longest follow-up investigations of organ-preserving focal therapy. Researchers evaluated 3,477 men treated with HIFU and cryotherapy over a ten-year period. The investigators reported an exceptionally low 10-year prostate cancer-specific mortality of just 0.13%, while only 3.3% of patients developed metastatic disease during long-term follow-up. Based on these findings, the authors concluded that organ-preserving focal HIFU may be considered alongside radical prostatectomy and radiotherapy as a first-line treatment option for appropriately selected patients with localized prostate cancer.

Importantly, the majority of patients treated with HIFU in this landmark registry received treatment using the Sonablate® High-Intensity Focused Ultrasound platform, representing the largest published body of long-term clinical evidence currently available for focal HIFU.

Scientific Focus at SOGOCON 2026

The growing confidence in organ-preserving focal therapy was also reflected at the 5th Annual Conference of the Society of Genitourinary Oncologists (SOGOCON 2026), held in Hyderabad under the theme “Precision Oncology in Action.” The official scientific programme featured a dedicated session titled “Focal Therapy for Localised Prostate Cancer – Ready for Routine Practice? (HIFU, Cryotherapy, IRE).” Its inclusion highlights the increasing recognition among India’s leading uro-oncology specialists that carefully selected patients may benefit from evidence-based organ-preserving treatment strategies that seek to balance effective cancer control with preservation of urinary and sexual function.

A Different Philosophy of Prostate Cancer Treatment

Unlike radical prostatectomy, which removes the entire prostate gland, targeted organ-preserving focal HIFU uses precisely focused ultrasound energy to destroy only the cancerous portion of the prostate while preserving healthy tissue whenever clinically appropriate.

For suitable patients, this minimally invasive approach aims to reduce urinary incontinence, preserve erectile function, minimise blood loss, shorten hospital stay and enable a faster recovery while maintaining effective cancer control. As international evidence continues to mature, organ-preserving focal HIFU is becoming an increasingly important component of multidisciplinary prostate cancer care.

The Art of Medicine Is Proven Over Time

Medical innovation creates new possibilities, but the true measure of progress is not technology alone—it is patient outcomes that stand the test of time.

The landmark 10-year evidence reflects more than advances in HIFU technology. It represents decades of physician experience, continuous clinical refinement, thoughtful patient selection and the evolution of evidence-based organ-preserving focal therapy.

Every prostate cancer is different, and every prostate anatomy is unique. Successful focal therapy requires physicians to accurately interpret multiparametric MRI, understand tumour biology, define appropriate treatment margins and individualise treatment before and throughout the procedure. Precision is therefore achieved through the combination of advanced technology, physician expertise, long-term evidence and sound clinical judgement—not technology alone.

Designed around a physician-directed treatment philosophy, the Sonablate® HIFU platform provides real-time visualisation and treatment control, enabling experienced physicians to personalise treatment according to each patient’s anatomy, disease characteristics and clinical needs.

Growing Need and Clinical Experience in India

Prostate cancer is among the fastest-growing cancers affecting Indian men. Increased awareness, wider availability of PSA testing, multiparametric MRI and targeted biopsy are enabling more patients to be diagnosed at an earlier stage, when organ-preserving focal therapy may be considered.

Several leading Indian institutions have incorporated HIFU into multidisciplinary prostate cancer programmes for appropriately selected patients, including Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, Tata Memorial Hospital, Mumbai, and Kokilaben Dhirubhai Ambani Hospital, Mumbai. These centres reflect India’s growing expertise in precision, minimally invasive and image-guided prostate cancer treatment.

Commenting on the evolution of HIFU in India, Dr. Sudhir Rawal, Medical Director and Chief of Genitourinary Oncology at Rajiv Gandhi Cancer Institute & Research Centre, said that the transition from whole-gland HIFU to organ-preserving focal therapy represents a significant advancement in prostate cancer care. He noted that long-term evidence is encouraging, but emphasised that optimal outcomes depend on careful patient selection, high-quality imaging, multidisciplinary evaluation and experienced clinical teams.

Why This Matters

For most Indian families, cancer affects far more than one individual. It impacts spouses, children, parents, careers and emotional well-being.

The emergence of organ-preserving focal HIFU represents an important shift in treatment philosophy. Rather than focusing solely on eliminating cancer, it seeks—where medically appropriate—to preserve the patient’s quality of life while achieving effective oncological outcomes.

Experts emphasise that organ-preserving focal HIFU is not suitable for every patient. Careful selection based on PSA levels, multiparametric MRI, targeted biopsy, tumour characteristics and multidisciplinary evaluation remains essential to achieving the best possible clinical outcomes.

Looking Ahead

The convergence of robust 10-year international evidence and growing scientific engagement at India’s leading uro-oncology conference marks an important milestone in the evolution of localized prostate cancer care.

As physician experience, imaging technology and personalised treatment strategies continue to evolve, organ-preserving focal HIFU is expected to play an increasingly important role in multidisciplinary prostate cancer management for appropriately selected patients.

The evolution of focal therapy also reinforces an enduring principle of modern medicine: while technology continues to advance, long-term patient outcomes, physician expertise, thoughtful patient selection and continuous clinical refinement remain the true foundations of successful cancer care.

For thousands of Indian men diagnosed with localized prostate cancer, this growing body of evidence offers something deeply meaningful—hope that, for carefully selected patients, effective cancer treatment no longer has to mean sacrificing the quality of life they cherish. It represents an important step towards a future where precision, personalization and organ preservation become integral to prostate cancer care in India.